Korean J Hematol.  2010 Mar;45(1):62-65. 10.5045/kjh.2010.45.1.62.

Neostigmine for the treatment of acute colonic pseudo-obstruction (ACPO) in pediatric hematologic malignancies

Affiliations
  • 1Department of Pediatrics, College of Medicine, The Catholic University of Korea, Seoul, Korea. chobinkr@catholic.ac.kr
  • 2Department of Radiology, College of Medicine, The Catholic University of Korea, Seoul, Korea.

Abstract

BACKGROUND
Acute colonic pseudo-obstruction (ACPO) refers to dilatation of the colon and decreased bowel motility without evidence of mechanical obstruction. Neostigmine, an acetylcholinesterase inhibitor, has been used in patients in whom supportive therapy failed to resolve ACPO. Here, we report the results of administering neostigmine to treat ACPO in children with hematologic malignancies.
METHODS
Between September 2005 and December 2009, 10 patients (8 male and 2 female) were diagnosed with ACPO at the Department of Pediatrics, Catholic University of Korea. Diagnosis of ACPO was based on typical clinical features as well as colonic dilatation found on abdominal CT imaging. Neostigmine was administered subcutaneously at a dosage of 0.01 mg/kg/dose (maximum 0.5 mg) twice daily for a maximum of 5 total doses. ACPO was determined to be responsive to neostigmine if the patient showed both stool passage and improvement of clinical symptoms.
RESULTS
The study group included 8 acute lymphoblastic leukemia patients, 1 patient with malignant lymphoma, and 1 patient with juvenile myelomonocytic leukemia. The median age at ACPO diagnosis was 8.5 years (range, 3-14). Overall, 8 patients (80%) showed therapeutic response to neostigmine at a median of 29 hours after the initial administration (range, 1-70). Two patients (20%) showed side effects of grade 2 or above, but none complained of cardiovascular symptoms that required treatment.
CONCLUSION
In this study, ACPO was diagnosed most often in late-childhood ALL patients. Subcutaneous neostigmine can be used to effectively treat ACPO diagnosed in children with hematologic malignancies without major cardiovascular complications.

Keyword

Acute colonic pseudo-obstruction; Neostigmine; Children; Hematologic malignancies

MeSH Terms

Acetylcholinesterase
Child
Colon
Colonic Pseudo-Obstruction
Dilatation
Hematologic Neoplasms
Humans
Korea
Leukemia, Myelomonocytic, Juvenile
Lymphoma
Male
Neostigmine
Pediatrics
Precursor Cell Lymphoblastic Leukemia-Lymphoma
Acetylcholinesterase
Neostigmine

Figure

  • Fig. 1 An 11-year-old male patient diagnosed with Philadelphia chromosome-positive ALL failed to pass stools for 157 hours before an abdominal CT was undertaken. Initial imaging showed massive colonic dilatation and fecal impaction consistent with ACPO, with the maximum diameter of the ascending colon measuring approximately 6.7 cm (A). Four hours after imaging, the patient was started on subcutaneous neostigmine, which resulted in stool passage 1 hour later. The patient received 1 more infusion for rapid amelioration of symptoms. Follow-up imaging taken 7 days later showed improvement in both colonic dilatation and fecal loading with a decrease in the maximum diameter of the ascending colon to 4.8 cm (B).


Reference

1. Saunders MD. Acute colonic pseudo-obstruction. Best Pract Res Clin Gastroenterol. 2007; 21:671–687. PMID: 17643908.
Article
2. Ponec RJ, Saunders MD, Kimmey MB. Neostigmine for the treatment of acute colonic pseudo-obstruction. N Engl J Med. 1999; 341:137–141. PMID: 10403850.
3. van der Spoel JI, Oudemans-van Straaten HM, Stoutenbeek CP, Bosman RJ, Zandstra DF. Neostigmine resolves critical illness-related colonic ileus in intensive care patients with multiple organ failure--a prospective, double-blind, placebo-controlled trial. Intensive Care Med. 2001; 27:822–827. PMID: 11430537.
4. McNamara R, Mihalakis MJ. Acute colonic pseudo-obstruction: rapid correction with neostigmine in the emergency department. J Emerg Med. 2008; 35:167–170. PMID: 18242923.
Article
5. Rosenberg RF, Caridi JG. Vincristine-induced megacolon. Gastrointest Radiol. 1983; 8:71–73. PMID: 6832541.
Article
6. Williams EV, Drew PJ, Gaffney C, Shrestha BM, Mansel RE. Pancolitis associated with docetaxel: a rare cause of megacolon. Breast. 2001; 10:346–347. PMID: 14965607.
Article
7. Breccia M, Girmenia C, Mecarocci S, et al. Ogilvie's syndrome in acute myeloid leukemia: pharmacological approach with neostigmine. Ann Hematol. 2001; 80:614–616. PMID: 11732875.
8. Khosla A, Ponsky TA. Acute colonic pseudoobstruction in a child with sickle cell disease treated with neostigmine. J Pediatr Surg. 2008; 43:2281–2284. PMID: 19040954.
Article
9. Kim TS, Lee JW, Kim MJ, et al. Acute colonic pseudo-obstruction in postchemotherapy complication of brain tumor treated with neostigmine. J Pediatr Hematol Oncol. 2007; 29:420–422. PMID: 17551407.
Article
10. Legha SS. Vincristine neurotoxicity. Pathophysiology and management. Med Toxicol. 1986; 1:421–427. PMID: 3540519.
11. Gomber S, Dewan P, Chhonker D. Vincristine induced neurotoxicity in cancer patients. Indian J Pediatr. 2010; 77:97–100. PMID: 19936661.
Article
Full Text Links
  • KJH
Actions
Cited
CITED
export Copy
Close
Share
  • Twitter
  • Facebook
Similar articles
Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr